Stefan Ambs
Senior Investigator
Center for Cancer Research
National Cancer Institute
United States of America
Biography
Dr. Stefan Ambs earned a Master's degree in Biochemistry from the University of Tuebingen (1988) and a Master of Public Health degree (Epidemiology) from the Johns Hopkins Bloomberg School of Public Health (2005). He completed his Ph.D. thesis (1992) at the Institute of Toxicology, University of Wuerzburg, Germany, and was trained as a Postdoctoral Fellow at the Laboratory of Human Carcinogenesis (1992-1997), National Cancer Institute, Bethesda, Maryland. He continued his research at a biotechnology company in California and at the Aventis Genomics Center in Cambridge, Massachusetts. Dr. Ambs joined the NCI as a tenure-track investigator in November of 2001. He became a tenured Senior Investigator in 2010.
Research Interest
molecular epidemiology; cancer health disparities; cancer risk assessment; nitric oxide biology; cancer inflammation and angiogenesis; non-coding RNAs
Publications
-
Glynn SA, Boersma BJ, Dorsey TH, Yi M, Yfantis HG, Ridnour LA, Martin DN, Switzer CH, Hudson RS, Wink DA, Lee DH. Increased NOS2 predicts poor survival in estrogen receptor–negative breast cancer patients. The Journal of clinical investigation. 2010 Nov 1;120(11):3843.
-
Hudson RS, Yi M, Esposito D, Watkins SK, Hurwitz AA, Yfantis HG, Lee DH, Borin JF, Naslund MJ, Alexander RB, Dorsey TH. MicroRNA-1 is a candidate tumor suppressor and prognostic marker in human prostate cancer. Nucleic acids research. 2011 Dec 29;40(8):3689-703.
-
Terunuma A, Putluri N, Mishra P, Mathé EA, Dorsey TH, Yi M, Wallace TA, Issaq HJ, Zhou M, Killian JK, Stevenson HS. MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis. The Journal of clinical investigation. 2014 Jan 2;124(1):398.
